Akademik Veri Yönetim Sistemi
Hacettepe University Journal of the Faculty of Pharmacy, cilt.33, sa.2, ss.231-250, 2013 (Scopus)
© 2013, Hacettepe University, Faculty of Pharmacy. All rights reserved.The development of new drug candidates and cures for Central Nervous System (CNS) disorders is restricted owing to the Blood-Brain Barrier (BBB) formed by the endothelial tight junctions within the brain micro-vasculature. The BBB protects brain from toxic and harmful compounds, but it also represents an obstacle for a large number of drugs. Thus, there are number of Central Nervous System (CNS) diseases that cannot be treated owing to the BBB problem, except the small group of CNS disorders including schizophrenia, depression and insomnia. The lag in CNS drug development is due to the fact that drug discovering and drug targeting are conducted as two separate disciplines. The major point to catch up with the progress in any other developing area is to carry on the researches for new drug development and targeting together. The brain drug targeting strategies can be divided into two groups derived from either chemistry based or biology-based disciplines. For the past decades, there has been a research interest in the area of chemical approaches for BBB targeting. But nowadays, promising applications of brain drug targeting have been done based on biologic strategies by nanoparticulate systems targeting specific receptors expressed in brain capillary endothelial cells. Therefore, the aim of this present review is to follow the time line of previous approaches to access to the CNS for better understanding of the new strategies as well as the basis of novel targeting systems.